7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31 2009-12-31 2009-09-30 2009-06-30 2009-03-31 2008-09-30 2008-06-30 2008-03-31 2007-12-31 2007-09-30 2007-06-30 2007-03-31 2006-12-31 2006-09-30 2006-06-30 2006-03-31 2005-09-30 2005-06-30 2005-03-31 2004-09-30 
      
    		                                                                               
      cash flows from operating activities:
    		                                                                               
      net income
    		27,755,000 32,581,000 30,147,000 27,947,000 28,444,000 35,726,000 28,240,000 27,629,000 25,834,000 20,245,000 20,703,000 33,401,000 15,272,000 15,298,000 10,545,000 20,613,000 11,967,000 4,916,000 10,958,000 15,378,000 -3,009,000 -19,058,000 -3,154,000 -4,205,000 -3,398,000 6,859,000 6,195,000 9,189,000 16,618,000 10,941,000 5,269,000 6,806,000 -3,569,000 9,483,000 14,803,000 7,506,000 974,000 7,290,000 4,351,000 6,409,000 4,818,000 7,401,000 5,174,000 8,671,000 7,764,000 3,716,000 2,823,000 6,540,000 5,607,000 3,752,000 671,000 641,000 4,970,000 4,563,000 6,872,000 6,639,000 4,210,000 -1,973,000 5,715,000 4,508,000 5,067,000 6,085,000 5,841,000 5,537,000 5,200,000 5,818,000 4,317,000 4,728,000 4,295,000 3,596,000 2,969,000 3,053,000 3,325,000 3,522,000 2,401,000 3,327,000 4,682,000 4,074,000 4,187,566 
      adjustments to reconcile net income to net cash from operating activities:
    		                                                                               
      depreciation and amortization
    		31,316,000 31,021,000 29,292,000 28,616,000 26,403,000 24,091,000 23,599,000 23,626,000 24,043,000 21,779,000 20,537,000 20,492,000 20,410,000 20,436,000 20,466,000 20,893,000 20,756,000 21,017,000 21,400,000 23,612,000 23,418,000 23,720,000 23,320,000 23,593,000 23,497,000 22,662,000 22,348,000 19,110,000 17,657,000 17,495,000 15,284,000 14,194,000 13,679,000 12,950,000 12,759,000 12,161,000 11,889,000 10,000,000 9,705,000 9,680,000 9,489,000 9,188,000 9,068,000 9,210,000 9,126,000 8,891,000 8,702,000 8,616,000 8,197,000 8,046,000 7,683,000 5,810,000 4,944,000 4,778,000 4,678,000 4,794,000 4,291,000 3,892,000 3,383,000 3,290,000 3,291,000 3,270,000 3,029,000 2,681,000 2,567,000 2,548,000 2,565,000 2,554,000 2,350,000 2,297,000 2,243,000 2,197,000 2,080,000 2,035,000 1,963,000 1,449,000 1,273,000 1,213,000 1,188,875 
      gain on disposition of business
    		0                                                                               
      loss on sale or abandonment of property and equipment
    		231,000 228,000 87,000 1,275,000 136,000 44,000 35,000 1,077,000 84,000 4,470,000 207,000 184,000 84,000                                                                   
      write-off of certain intangible assets and other long-term assets
    		70,000 50,000 32,000 55,000 121,000 78,000 202,000 45,000 133,000   548,000 0 61,000 1,672,000 0 44,000   8,200,000 20,589,000 3,895,000 3,925,000                                                         
      amortization of right-of-use operating lease assets
    		2,927,000 2,782,000 2,984,000 2,980,000 2,980,000 2,941,000 3,122,000 2,686,000 2,686,000 3,273,000 2,662,000 2,575,000 2,698,000 2,537,000 2,584,000 2,777,000 2,867,000 3,004,000 3,070,000 3,224,000 3,183,000 3,205,000 3,134,000 3,030,000 3,352,000 2,910,000 2,964,000                                                     
      fair value adjustments related to contingent consideration liabilities
    		32,000 143,000 1,023,000 151,000 103,000                                                                           
      amortization of deferred credits
    		-25,000 -26,000 -26,000 -26,000 -25,000 -26,000 -26,000 -26,000 -26,000 -26,000 -26,000 -26,000 -27,000 -27,000 -27,000 -27,000 -27,000 -27,000 -27,000 -27,000 -34,000 -34,000 -35,000 -35,000 -34,000 -35,000 -35,000 -36,000 -35,000 -35,000 -36,000 -36,000 -35,000 -36,000 -40,000 -42,000 -43,000 -42,000 -43,000 -42,000 -44,000 -42,000 -43,000 -44,000 -43,000 -43,000 -45,000 -42,000 -33,000 -32,000 -32,000 -34,000 -25,000                           
      amortization and write-off of long-term debt issuance costs
    		1,414,000 1,414,000 1,414,000                                                                             
      stock-based compensation expense
    		13,612,000 10,873,000 9,078,000 9,515,000 6,713,000 7,011,000 5,234,000 5,987,000 5,797,000 5,580,000 3,969,000 4,351,000 4,598,000 4,451,000 4,642,000 4,501,000 4,857,000 3,137,000 3,595,000 4,071,000 4,063,000 3,428,000 2,777,000 2,467,000 2,626,000 2,523,000 1,766,000 1,623,000 1,673,000 1,565,000 1,256,000 1,192,000 1,192,000 1,114,000 577,000 593,000 503,000 786,000 624,000 600,000 558,000 565,000 520,000 456,000 341,000 324,000 339,000 395,000 289,000 324,000 459,000 463,000                            
      changes in operating assets and liabilities, net of acquisitions:
    		                                                                               
      trade receivables
    		-6,346,000 250,000 -7,560,000 -4,146,000 -2,639,000 -2,719,000 -4,182,000 -8,064,000 2,128,000 -1,100,000 -4,880,000 -6,053,000 409,000 -5,621,000 -3,851,000 -2,438,000 1,653,000 -2,549,000 -5,284,000 -2,624,000 -2,243,000 11,847,000 3,445,000 -11,114,000 14,420,000 -9,649,000 -11,557,000 -2,040,000 2,465,000 -14,781,000 -13,166,000 -1,881,000 2,285,000 -7,491,000 -5,757,000 -1,650,000 1,293,000 -5,624,000 -835,000 -2,348,000 -731,000 -459,000 -2,334,000 -4,401,000 -2,046,000 -3,037,000 -4,115,000 -2,745,000 1,490,000 -3,717,000 -1,473,000 945,000 -132,000            -1,545,000 159,000 1,505,000  308,000   -2,129,000 -314,000 -313,000 2,813,000     
      other receivables
    		-701,000 3,101,000 -284,000 -1,812,000 -4,171,000 206,000 -705,000 3,469,000 -1,327,000 1,752,000 -1,465,000 -1,515,000 -788,000 603,000 5,854,000 -7,245,000 -2,380,000 -196,000 -597,000 498,000 527,000 30,000 613,000 1,787,000 -355,000 -643,000 1,070,000 -3,009,000 -711,000 68,000 898,000 -3,054,000 -335,000 -542,000 374,000 -2,239,000 1,259,000 759,000 1,367,000 -389,000 -166,000 1,677,000 -735,000 -2,157,000 -132,000 -1,192,000 439,000 -174,000 28,000 123,000 -586,000 -270,000 -41,000   17,000   173,000 171,000  8,000 266,000 78,000 54,000 124,000 253,000             
      inventories
    		-3,353,000 -1,121,000 -10,599,000 557,000 -5,963,000 3,501,000 -382,000 2,321,000 1,076,000 -12,528,000 -22,974,000 -17,194,000 -15,969,000 -5,589,000 -9,177,000 -14,003,000 -14,365,000 6,581,000 -3,396,000 13,761,000 13,413,000 7,238,000 -4,983,000 -7,742,000 -14,164,000 -3,798,000 -1,340,000 -8,797,000 -12,186,000 -1,801,000 -5,388,000 -7,912,000 -7,762,000 -3,004,000 844,000 -3,876,000 1,623,000 869,000 -2,272,000 -5,681,000 -7,598,000 -3,352,000 3,518,000 1,157,000 -6,459,000 -1,742,000 -2,352,000 -827,000 122,000 890,000 2,149,000 -81,000 -3,354,000   245,000    353,000        2,634,000 1,426,000 588,000 408,000         
      prepaid expenses and other current assets
    		-463,000 -4,616,000 2,041,000 1,576,000 -3,565,000 -3,071,000 765,000 1,353,000 -150,000 -1,308,000 1,386,000 2,388,000 -2,031,000 -848,000 -1,307,000 2,696,000 -2,428,000 -2,752,000 -1,071,000 3,483,000 -2,580,000 1,777,000 -3,126,000 2,620,000 -2,807,000 -1,071,000 19,000 719,000 386,000 -1,882,000 -1,223,000                                                 
      income tax refund receivables
    		3,513,000 -5,796,000 2,143,000 5,994,000 -3,909,000 -3,926,000 305,000 8,624,000 -5,105,000 -3,307,000 -270,000 3,665,000 -1,709,000 -200,000 196,000 -221,000 969,000 -208,000 199,000 8,327,000 -1,337,000 -4,854,000 -2,475,000 6,433,000 -4,700,000 -3,538,000 -442,000 98,000 1,280,000 -941,000 -205,000 -868,000 -14,000 644,000 -350,000 -108,000 -358,000 448,000 424,000 -566,000 -140,000 461,000 -539,000 1,000 -14,000 -168,000 192,000                          27,000       
      other assets
    		-358,000 -1,295,000 -176,000 -2,206,000 -892,000 -21,000 -2,947,000 -5,257,000 839,000 -1,479,000 -79,000 -1,191,000 80,000 935,000 833,000 1,968,000 -2,953,000 -765,000 80,000 -2,423,000 -1,216,000 705,000 -577,000 -1,309,000 -987,000 -753,000 -2,092,000 1,685,000 -619,000 -260,000 -491,000 -743,000 -1,492,000 -328,000 -1,172,000 -2,172,000 -829,000 -871,000 109,000 414,000 2,111,000 -2,285,000 -602,000 -260,000 -487,000 206,000 -847,000 -883,000 -110,000 -436,000 -377,000 -309,000    22,000                        
      trade payables
    		-269,000 -756,000 4,453,000 4,175,000 607,000 7,052,000 -14,148,000 13,035,000 -13,079,000 -4,290,000 -2,963,000 2,909,000 6,039,000 1,043,000 2,670,000 4,869,000 -4,458,000 1,402,000 4,237,000 3,015,000 1,190,000 -8,212,000 4,340,000 1,480,000 -5,113,000 2,216,000 -878,000 -210,000 169,000 7,358,000 8,409,000 1,293,000 -4,540,000 2,625,000 1,039,000 2,183,000 -3,871,000 -7,547,000 2,400,000 5,028,000 4,516,000 5,138,000 84,000 4,671,000 -1,644,000 2,784,000 -485,000 4,073,000 -4,664,000 2,670,000 -2,084,000 1,916,000 1,892,000    5,326,000 -28,000   -2,806,000 -407,000 1,728,000 1,781,000 -829,000 -91,000 1,392,000     220,000 -286,000 -166,000 537,000 1,448,000 -1,552,000 1,630,000 127,180 
      accrued expenses
    		7,589,000 18,007,000 -20,747,000 10,329,000 2,190,000 6,087,000 -8,891,000 -1,885,000 9,696,000 -6,724,000 -3,571,000 -7,518,000 12,105,000 2,542,000 -23,508,000 16,887,000 10,369,000 3,813,000 5,393,000 -17,988,000 2,927,000 21,285,000 -1,621,000 9,514,000 -1,859,000 5,375,000 -3,450,000 4,999,000 240,000 9,862,000 -2,395,000 1,947,000 -3,319,000 4,548,000 3,285,000 1,552,000 -1,346,000 6,975,000 -3,936,000 -1,361,000 2,542,000 1,822,000 2,653,000 1,451,000 1,147,000 671,000 2,868,000 -127,000 3,556,000 -1,425,000 -2,280,000 1,655,000 -1,272,000 2,288,000   549,000 573,000   -977,000 949,000 1,086,000 570,000 541,000 1,045,000 209,000 -433,000 17,000 1,089,000 199,000  -490,000       
      income taxes payable
    		1,948,000 -381,000 1,918,000 461,000 1,623,000 -7,520,000 3,651,000 1,746,000 1,465,000 -7,554,000 2,658,000 5,895,000 -2,488,000 -33,000 1,147,000 1,481,000 -740,000 -686,000 -174,000 -1,165,000 -493,000 -537,000 2,109,000 577,000 1,131,000 -1,180,000 -879,000 2,446,000 548,000 -1,596,000 -480,000 785,000 -463,000 -279,000 -22,000 1,634,000 -1,803,000 1,042,000 578,000 -1,847,000 1,137,000 1,532,000 1,377,000 -2,165,000 2,489,000 668,000 91,000 393,000 1,181,000 -1,285,000 -34,000 -613,000 -3,910,000 1,271,000 2,595,000 2,702,000 -1,462,000 309,000 578,000 1,612,000 -1,034,000 -353,000 77,000 2,135,000 1,279,000 -1,444,000 1,855,000 875,000 -234,000 -377,000 1,331,000 1,169,000 593,000 207,000 755,000   964,000 -1,164,004 
      deferred compensation payable
    		-2,717,000 1,183,000 -580,000 -21,000 630,000 360,000 1,061,000 1,658,000 -909,000 549,000 605,000 477,000 -776,000 -1,242,000 -1,307,000 697,000 359,000 828,000 -581,000 1,412,000 1,202,000 128,000 -789,000 1,359,000 758,000 257,000 1,261,000 -955,000 556,000 435,000 3,000 863,000 594,000 326,000 187,000 212,000 -103,000 908,000 -305,000 -433,000 -524,000 349,000 473,000 158,000 112,000 250,000 282,000 1,012,000 218,000 366,000 281,000 533,000 203,000 -286,000 191,000 219,000 757,000 83,000 -23,000 59,000 334,000 312,000                 188,006 
      operating lease liabilities
    		-2,653,000 -2,590,000 -3,335,000 -3,127,000 -3,094,000 -3,031,000 -2,931,000 -2,919,000 -2,862,000 -3,474,000 -2,237,000 -2,721,000 -2,797,000 -2,768,000 -2,841,000 -3,045,000 -3,106,000 -3,108,000 -3,151,000 -3,261,000 -3,221,000 -3,232,000 -2,945,000 -3,014,000 -3,074,000 -2,828,000 -3,054,000                                                     
      other long-term obligations
    		1,460,000 -1,496,000 -733,000 -1,929,000 164,000 -60,000 2,854,000 -212,000 -74,000 -1,855,000 -389,000 787,000 -796,000 -287,000 574,000 -1,059,000 -62,000 207,000 56,000 -984,000 2,575,000 2,194,000 -179,000 -7,085,000 2,976,000 1,060,000 1,148,000 580,000 -1,202,000 158,000 -337,000 1,936,000 -333,000 117,000 790,000 51,000 -39,000 -136,000 -76,000 1,167,000 -39,000 208,000 433,000 -198,000 318,000 496,000 -50,000 -787,000 -3,485,000 -421,000 294,000 -403,000 -1,046,000 560,000 377,000 39,000        2,000                
      total adjustments
    		47,227,000 50,726,000 10,425,000 40,797,000 18,889,000 32,780,000 7,976,000 34,622,000 25,235,000 -2,959,000 -6,158,000 -5,393,000 20,217,000 23,486,000 1,465,000 25,202,000 13,009,000 36,292,000 24,274,000 21,537,000 58,148,000 63,410,000 32,018,000 31,114,000 18,612,000 15,326,000 7,310,000 14,487,000 11,190,000 16,173,000 2,666,000 12,528,000 12,396,000 9,905,000 375,000 9,755,000 9,920,000 6,571,000 7,232,000 6,044,000 11,805,000 13,709,000 14,098,000 13,069,000 3,682,000 8,463,000 5,137,000 11,209,000 13,652,000 7,720,000 2,222,000 14,135,000 337,000 10,538,000   9,929,000 7,733,000 4,076,000 562,000 1,499,000 244,000 1,986,000 3,811,000 -2,050,000 438,000 5,286,000 5,485,000 4,175,000 4,046,000 2,825,000 1,306,000 -91,000 639,000 4,951,000   1,001,000 3,164,670 
      net cash, cash equivalents, and restricted cash from operating activities
    		74,982,000 83,307,000 40,572,000 68,744,000 47,333,000 68,506,000 36,216,000 62,251,000 51,069,000 17,286,000 14,545,000 28,008,000 35,489,000 38,784,000 12,010,000                                                                 
      ​
    		                                                                               
      cash flows from investing activities:
    		                                                                               
      capital expenditures for:
    		                                                                               
      property and equipment
    		-22,440,000 -13,751,000 -21,061,000 -3,472,000 -9,359,000 -10,627,000 -11,682,000 -7,139,000 -8,595,000 -5,771,000 -12,785,000 -12,490,000 -15,776,000 -7,237,000 -9,526,000 -8,327,000 -6,795,000 -6,646,000 -6,171,000 -10,398,000 -9,787,000 -11,853,000 -13,950,000 -20,069,000 -22,145,000 -17,704,000 -18,255,000 -16,300,000 -15,465,000 -15,320,000 -16,239,000 -9,101,000 -11,740,000 -7,604,000 -10,178,000 -6,345,000 -5,270,000 -10,231,000 -10,991,000 -11,458,000 -14,135,000 -15,874,000 -9,492,000 -9,919,000 -5,546,000 -10,008,000 -8,708,000 -11,470,000 -17,646,000 -10,428,000 -19,961,000 -15,379,000 -22,109,000                           
      intangible assets
    		-1,031,000 -839,000 -457,000 -765,000 -562,000 -715,000 -861,000 -655,000 -709,000 -776,000 -271,000 -1,266,000 -997,000 -570,000 -342,000 -713,000 -652,000 -777,000 -692,000 -789,000 -709,000 -728,000 -1,062,000 -764,000 -953,000 -754,000 -853,000 -778,000 -479,000 -870,000 -885,000 -650,000 -845,000 -414,000 -668,000 -623,000 -605,000 -507,000 -482,000 -571,000 -510,000 -380,000 -495,000 -346,000 -443,000 -492,000 -433,000                                 
      proceeds from the sale of property and equipment
    		4,000   0 3,000   20,000 -20,000 1,000 200,000 2,000 4,000   0 153,000 11,000 873,000 9,000 6,000   658,000 240,000 19,000 3,000 48,000 3,000 1,000 3,000 12,000 6,000 0 3,000 14,000    1,205,000 36,000 3,000 3,000 36,000 41,000 3,000 18,000 41,000 19,000 45,000 8,000 34,000 0    1,000 6,000 3,000 7,000 4,000 8,000          1,000 12,000   0   1,287 
      proceeds from disposition of business
    		0                                                                               
      cash paid for notes receivable and other investments
    		-319,000 -7,500,000 -7,117,000                                                                             
      cash paid in acquisitions, net of cash acquired
    		-279,000 -121,555,000 -1,000,000    -3,346,000 0 71,000 -136,349,000 -2,000,000 -3,575,000 0   -5,313,000 0 -1,500,000 -358,000 -10,693,000 -160,000   -392,000 -16,256,000 -35,314,000 -1,942,000 -179,019,000 -4,116,000 -18,459,000 -100,195,000 -2,082,000 -48,691,000 -7,348,000 -47,461,000 -5,353,000 -97,008,000 -1,300,000 -21,500,000 -500,000 -9,618,000 -1,000,000 -1,250,000 -1,725,000 -2,752,000                                   
      net cash, cash equivalents, and restricted cash from investing activities
    		-24,065,000 -143,351,000 -29,635,000 -214,447,000 -115,668,000 -16,487,000 -22,051,000 -8,343,000 -9,253,000 -142,895,000 -14,856,000 -17,329,000 -16,769,000 -13,431,000 -9,868,000                                                                 
      see condensed notes to consolidated financial statements.
    		                                                                               
      (gain) loss on disposition of business
    		                                                                               
      acquired in-process research and development
    		       0 0   0 0           0 0 500,000 25,000 262,000 76,000   0 12,061,000   61,000 300,000   0            0 2,400,000                           
      deferred income taxes
    		                               -1,014,000 5,000 92,000 -387,000 -1,149,000 46,000 -29,000 170,000 2,494,000 573,000 -79,000 462,000 4,054,000 -203,000 -2,000 21,000 1,372,000 -7,000 -8,000 2,000 535,000 1,214,000 357,000 13,000 93,000    1,000    2,000    -348,000 835,000       394,000 3,000 73,000  
      changes in operating assets and liabilities, net of acquisitions and divestitures:
    		                                                                               
      prepaid income taxes
    		       -68,000            -127,000      8,000 -53,000 -324,000 -20,000 -28,000 -72,000 -380,000 -139,000 -3,000 -89,000 467,000 55,000 -80,000 -38,000 -1,745,000 0 -95,000 52,000 -74,000 30,000   35,000 -25,000 -9,000 17,000 -369,000                            
      liabilities related to unrecognized tax benefits
    		                                   963,000    1,240,000    768,000 -580,000   383,000    784,000                            
      proceeds (payments) from disposition of business
    		                                                                               
      see notes to consolidated financial statements.
    		                                                                               
      amortization of long-term debt issuance costs
    		    1,477,000 1,477,000 1,477,000  282,000 311,000 151,000 151,000 151,000 151,000 151,000 151,000 151,000 151,000 151,000 151,000 151,000 151,000 151,000 151,000 168,000 201,000 201,000 201,000 201,000 201,000 201,000 171,000 171,000 172,000 171,000 173,000 258,000 264,000 257,000 246,000 247,000 247,000 247,000 246,000 247,000 247,000 247,000 247,000 199,000 200,000 199,000                             
      issuance of note receivables
    		    -500,000 0 -6,162,000                                                                         
      cash paid in acquisitions and investments, net of cash acquired
    		    -105,250,000                                                                           
      adjustments related to contingent consideration liabilities
    		      -117,000  562,000 1,094,000 521,000                                                                     
      cash received for settlement of note receivable
    		                                                                               
      issuance of note receivable
    		                            -250,000                                                   
      loss on disposition of business
    		            135,000                                                                   
      payments from disposition of business
    		            0                                                                   
      adjustments and payments related to contingent consideration liability
    		            889,000                                                                   
      gain on sales and/or abandonment of property and equipment
    		              94,000                                  112,000                               
      fair value adjustments to contingent consideration
    		              2,600,000 -161,000 1,115,000 1,805,000 402,000 -8,844,000 -4,356,000 343,000 4,897,000                                                         
      gain on sale of business
    		                   -9,000                                                            
      loss on sales and/or abandonment of property and equipment
    		               673,000 388,000 270,000 -28,000 856,000 933,000 333,000 37,000 -522,000 -166,000 515,000 288,000  54,000 20,000 351,000                    7,000                             
      long-term income taxes payable
    		                                                                               
      net cash from operating activities
    		               45,815,000 24,976,000 41,208,000 35,232,000 36,915,000 55,139,000 44,352,000 28,864,000 26,909,000 15,214,000 22,185,000 13,505,000 23,676,000 27,808,000 27,114,000 7,935,000 19,334,000 8,827,000 19,388,000 15,178,000 17,261,000 10,894,000 13,861,000 11,583,000 12,453,000 16,623,000 21,110,000 19,272,000 21,740,000 11,446,000 12,179,000 7,960,000 17,749,000 19,259,000 11,472,000 2,893,000 14,776,000 5,307,000 15,101,000 9,004,000 4,603,000 14,139,000 5,760,000 9,791,000 5,070,000 6,566,000 6,329,000 7,827,000 9,348,000 3,150,000 6,256,000 9,603,000 10,213,000 8,470,000 7,642,000 5,794,000 4,359,000 3,234,000 4,161,000 7,352,000   5,075,000 7,352,236 
      proceeds from sale of business
    		                   0                                                            
      net cash from investing activities
    		               -14,607,000 -7,294,000 -8,912,000 -6,348,000 -21,871,000 -9,365,000 -12,654,000 -14,762,000 -20,567,000 -39,114,000 -53,753,000 -21,047,000 -196,049,000 -20,307,000 -45,148,000 -117,316,000 -11,821,000 -61,270,000 -15,366,000 -58,304,000 -12,307,000 -102,878,000 -12,038,000 -31,884,000 -11,324,000 -24,227,000 -17,057,000 -9,411,000 -9,617,000 -5,516,000 -11,947,000 -9,123,000 -18,503,000 -18,109,000 -10,650,000 -21,347,000 -184,953,000 -26,921,000                           
      cash received for settlement of current note receivable
    		                   0 0 0 250,000                                                         
      changes in operating assets and liabilities, net of effects from acquisitions:
    		                                                                               
      gain on bargain purchase
    		                               -243,000 778,000 669,000 -12,243,000                                             
      write-off of patents and intangible assets
    		                        2,898,000   70,000 658,000 29,000 57,000 902,000 67,000 1,000 18,000 11,000 0   42,000 85,000 0 14,000 67,000   34,000 39,000                                
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2019 and 2018
    		                                                                               
      cash flows from financing activities:
    		                                                                               
      proceeds from issuance of common stock
    		                         1,641,000 1,733,000 1,717,000 210,025,000 1,740,000 1,511,000 741,000 2,080,000 2,420,000 138,569,000 849,000 3,631,000 234,000 557,000 744,000 780,000 1,123,000 4,021,000 4,335,000 283,000 2,725,000 803,000 2,570,000 283,000 305,000 571,000 429,000          1,025,000 284,000 101,000   1,725,000      949,000       
      proceeds from issuance of long-term debt
    		                         82,627,000 43,119,000 258,283,000 59,998,000 63,856,000 256,971,000 45,752,000 54,603,000 13,136,000 83,723,000 16,027,000 109,666,000 38,628,000 55,184,000 42,470,000 44,566,000 33,536,000 31,803,000 35,236,000 37,048,000 35,724,000 36,010,000                                 
      payments on long-term debt
    		                         -66,627,000 -54,119,000 -72,033,000 -264,748,000 -36,856,000 -148,971,000 -45,252,000 -18,603,000 -8,636,000 -170,723,000 -19,440,000 -12,971,000 -35,311,000 -34,376,000 -45,095,000 -44,121,000 -36,641,000 -43,415,000 -51,620,000 -45,559,000 -41,790,000 -30,423,000 -68,843,000 -44,724,000 -34,398,000 -17,512,000 -29,650,000                            
      contingent payments related to acquisitions
    		                         -57,000 -554,000 -47,000 -54,000 -115,000 -15,000 -16,000 -15,000 -15,000 -15,000 -19,000 -16,000 -16,000 -167,000 -1,018,000 -14,000 -14,000 -166,000 -12,000 -17,000 -14,000 -24,000 -17,000 -22,000 -19,000 -19,000 -21,000                            
      net cash from financing activities
    		                         17,584,000 -9,821,000 187,920,000 2,239,000 28,625,000 109,496,000 809,000 38,064,000 6,923,000 50,721,000 -2,441,000 98,815,000 3,526,000 21,195,000 -2,747,000 1,504,000 -1,715,000 -7,277,000 -11,757,000 -8,238,000 -3,287,000 6,314,000 -946,000 -5,239,000 2,911,000 18,042,000 170,482,000               1,973,000    877,000  1,104,000 640,000 800,000 1,892,000 1,117,000 506,000 455,786 
      effect of exchange rates on cash
    		                         -356,000 -474,000 -143,000 -1,297,000 -1,250,000 1,720,000 652,000 66,000 266,000 -302,000 -660,000 0 -24,000 91,000 -64,000 -143,000 -144,000 -31,000 551,000 -655,000 -135,000 -19,000 44,000 61,000 393,000 -290,000 -51,000              207,000 158,000  184,000 22,000 86,000  1,000 119,000 11,000     
      net increase in cash and cash equivalents
    		                         -14,340,000 -17,837,000 15,404,000 8,443,000 9,341,000 1,835,000 8,974,000 -14,313,000 11,211,000 7,293,000 1,853,000 6,831,000 5,325,000 985,000   2,194,000 2,553,000   -3,190,000 5,132,000     254,000                       4,369,000    -1,431,059 
      cash and cash equivalents:
    		                                                                               
      beginning of period
    		                         0 67,359,000  0 0 32,336,000  0 0 19,171,000  0 0 4,177,000  0 0 7,355,000  0 0 7,459,000  0 0 9,719,000           0 0 34,030,000  0 17,574,000  0 0 9,838,000  0 0 4,645,000 0 0 33,037,000 -83 
      end of period
    		                         -14,340,000 49,522,000  8,443,000 9,341,000 34,171,000  -14,313,000 11,211,000 26,464,000  6,831,000 5,325,000 5,162,000  -6,243,000 2,194,000 9,908,000  -2,963,000 -3,190,000 12,591,000  -4,028,000 4,126,000 9,017,000           890,000 -11,557,000 16,430,000  2,999,000 23,757,000  2,918,000 -364,000 9,645,000  -639,000 -1,370,000 9,014,000 -6,859,000 -9,782,000 28,617,000 -1,431,142 
      supplemental disclosures of cash flow information
    		                                                                               
      cash paid during the period for:
    		                                                                               
      interest
    		                         3,073,000 2,721,000 2,306,000 2,304,000 3,331,000 2,383,000 1,754,000 1,567,000 1,643,000 2,743,000 2,649,000 3,311,000 1,534,000 1,378,000 1,560,000 1,434,000 2,025,000 1,254,000 1,810,000 2,235,000 2,325,000 2,644,000 2,496,000 2,411,000 1,477,000 1,493,000 196,000          29,000 9,000 2,000  3,000 2,000  -1,000 1,000 3,000  2,000 3,000 2,000 13,000 0 5,000 363 
      income taxes
    		                         6,922,000 1,934,000 2,623,000 928,000 3,331,000 1,810,000 2,020,000 1,351,000 1,107,000 1,571,000 81,000 657,000 1,152,000 428,000 504,000 696,000 1,278,000 931,000 610,000 768,000 1,129,000 782,000 -1,289,000 953,000 668,000 403,000 648,000          2,854,000 3,063,000 463,000  4,733,000 2,876,000  1,668,000 1,634,000 218,000  1,555,000 1,428,000 36,000 1,260,000 2,427,000 1,221,000 2,179,248 
      supplemental disclosures of non-cash investing and financing activities
    		                                                                               
      property and equipment purchases in accounts payable
    		                         -1,257,000 4,588,000 1,931,000 -885,000 2,191,000 1,752,000 598,000 -166,000 804,000 756,000 -311,000 1,212,000 -87,000 1,584,000 878,000 -31,000 609,000 1,743,000 -957,000 420,000 -1,747,000 5,180,000 -1,285,000 -7,032,000 7,018,000 5,354,000 4,943,000          118,000 -113,000 1,689,000                
      acquisition purchases in accrued expenses and other long-term obligations
    		                               -1,512,000 6,000,000       0            149,000                            
      merit common stock surrendered (0 and 32 shares, respectively) in exchange for exercise of stock options
    		                                                                               
      right-of-use operating lease assets obtained in exchange for operating lease liabilities
    		                         1,765,000 1,162,000                                                     
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2019 and 2018
    		                                                                               
      losses on sales and/or abandonment of property and equipment
    		                                -15,000 22,000 212,000  58,000 15,000 29,000  68,000 16,000 37,000 367,000   91,000      28,000 -1,000 0 4,000 84,000 169,000 172,000 108,000 54,000 16,000 -4,000 205,000                
      excess tax benefits from stock-based compensation
    		                                   -142,000 -539,000 9,000 3,000 -152,000 -552,000 -560,000 -860,000 -333,000 -7,000 -68,000 -168,000 -114,000 -21,000 -177,000 53,000 -1,593,000          339,000 50,000 372,000  47,000 263,000  38,000 46,000 132,000  147,000 192,000 169,000     
      proceeds from sale of cost method investment
    		                                   0 0 0 1,089,000                                         
      issuance of notes receivable
    		                                                                               
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2018, 2017 and 2016
    		                                                                               
      offering costs
    		                           0                                                    
      long-term debt issuance costs
    		                                   0                                            
      payment of taxes related to an exchange of common stock
    		                           0        0    0 -258,000 -280,000 -380,000 -29,000 0 0 -220,000 0 0   -152,000                            
      beginning of year
    		                                                                               
      end of year
    		                                                                               
      cash paid during the year for:
    		                                                                               
      contingent receivable in exchange for sale of equity investment
    		                                                                               
      receivable for issuance of common stock associated with option exercises
    		                                                                               
      merit common stock surrendered (43, 0 and 14 shares, respectively) in exchange for exercise of stock options
    		                                                                               
      merit medical systems, inc. and subsidiaries
    		                                                                               
      consolidated statements of cash flows
    		                                                                               
      for the nine months ended september 30, 2018 and 2017
    		                                                                               
      merit common stock surrendered (43 and 0 shares, respectively) in exchange for exercise of stock options
    		                                                                               
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2018 and 2017
    		                                                                               
      merit common stock surrendered (32 and 0 shares, respectively) in exchange for exercise of stock options
    		                                                                               
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2018 and 2017
    		                                                                               
      losses (gains) on sales and/or abandonment of property and equipment
    		                                                                               
      proceeds from sale-leaseback transactions
    		                                       0 0 194,000 1,823,000                                     
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2017, 2016 and 2015
    		                                                                               
      cost method investment converted to intangible asset in acquisition in lieu of additional cash payment
    		                                       0                                        
      contingent receivable in exchange for sale of cost method investment
    		                                                                               
      merit common stock surrendered (0, 14 and 185 shares, respectively) in exchange for exercise of stock options
    		                                                                               
      fair value changes in contingent liabilities/assets
    		                                                                               
      employee receivables
    		                                0 18,000 36,000 -27,000 -9,000 94,000 -43,000 -15,000 -57,000 26,000 -6,000 2,000 0 9,000 35,000 25,000 -51,000 -9,000 -18,000 67,000 26,000    22,000   11,000    8,000 3,000   -22,000 16,000 47,000 11,000    3,000     
      prepaid expenses and other assets
    		                                -357,000 -1,459,000 229,000                             42,000   233,000           57,000  
      advances from employees
    		                                368,000 -326,000 -86,000 47,000 69,000 269,000 -388,000 53,000 -98,000 -177,000 439,000 -457,000 228,000 -138,000 509,000 -441,000 22,000 52,000 90,000 -91,000 -566,000   15,000 -12,000 -343,000 -109,000 563,000  -23,000 105,000 105,000 71,000           -42,000    
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2017 and 2016
    		                                                                               
      payment of offering costs related to issuance of common stock
    		                                -1,000 18,000 -833,000                                             
      merit common stock surrendered (0 and 14 shares, respectively) in exchange for exercise of stock options
    		                                                                               
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2017 and 2016
    		                                                                               
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2017 and 2016
    		                                                                               
      prepaid expenses
    		                                   723,000 1,774,000 -1,728,000 -498,000 -197,000 132,000 -471,000 -160,000 550,000 -242,000 285,000 -651,000 -56,000 -33,000 573,000 -1,242,000 1,334,000                            
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2016, 2015 and 2014
    		                                                                               
      receivable due for sale of equipment
    		                                                                               
      merit common stock surrendered (14, 185 and 127 shares, respectively) in exchange for exercise of stock options
    		                                                                               
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2016 and 2015
    		                                                                               
      supplemental disclosure of non-cash investing and financing activities
    		                                                                               
      contingent receivable received in exchange for sale of cost method investment
    		                                    30,000 0 681,000                                         
      merit common stock surrendered (14 and 185 shares, respectively) in exchange for exercise of stock options
    		                                                                               
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2016 and 2015
    		                                                                               
      acquisition purchases in accrued expenses
    		                                                                               
      merit common stock surrendered (0 and 166 shares, respectively) in exchange for exercise of stock options
    		                                                                               
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2016 and 2015
    		                                                                               
      merit common stock surrendered (0 and 89 shares, respectively) in exchange for exercise of stock options
    		                                                                               
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2015, 2014 and 2013
    		                                                                               
      proceeds from industrial assistant grants
    		                                               -511,000 150,000 0 750,000 705,000                            
      net decrease in cash and cash equivalents
    		                                       -1,682,000           -702,000                             
      merit common stock surrendered (185, 127 and 45 shares, respectively) in exchange for exercise of stock options
    		                                                                               
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2015 and 2014
    		                                                                               
      merit common stock surrendered (185 and 108 shares, respectively) in exchange for exercise of stock options
    		                                                                               
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2015 and 2014
    		                                                                               
      merit common stock surrendered (166 and 108 shares, respectively) in exchange for exercise of stock options
    		                                                                               
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2015 and 2014
    		                                                                               
      merit common stock surrendered (89 and 108 shares, respectively) in exchange for exercise of stock options
    		                                          1,725,000                                     
      impairment of cost-method investment
    		                                                                               
      realized gain on sale of marketable securities
    		                                                   0                            
      proceeds from the sale of marketable securities
    		                                                   0     0                       
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2014, 2013 and 2012
    		                                                                               
      net (decrease) in cash and cash equivalents
    		                                                                               
      acquisition of customer list in exchange for a settlement of trade receivables
    		                                                   -1,000                            
      merit common stock surrendered (127, 45 and 131 shares, respectively) in exchange for exercise of stock options
    		                                                                               
      proceeds from sale-leaseback transaction
    		                                                                               
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2014 and 2013
    		                                                                               
      merit common stock surrendered (108 and 45 shares, respectively) in exchange for exercise of stock options
    		                                            0                                   
      write-off of patents
    		                                                 51,000 2,000                             
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2014 and 2013
    		                                                                               
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2014 and 2013
    		                                                                               
      merit common stock surrendered (108 and 0 shares, respectively) in exchange for exercise of stock options
    		                                              1,641,000                                 
      purchase of marketable securities
    		                                                                               
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2013, 2012 and 2011
    		                                                                               
      merit common stock surrendered (45, 131 and 78 shares, respectively) in exchange for exercise of stock options
    		                                                                               
      income tax refund receivable
    		                                                -546,000 1,855,000 -782,000 193,000       103,000 16,000                    
      patents and trademarks
    		                                                -482,000 -267,000 -394,000  -309,000                           
      cash paid in acquisitions
    		                                                0 0 -1,000,000                             
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2013 and 2012
    		                                                                               
      borrowings under long-term debt
    		                                                39,053,000 36,973,000 34,199,000                             
      supplemental disclosures of cash flow information:
    		                                                                               
      supplemental disclosures of non-cash investing and financing activities:
    		                                                                               
      merit common stock surrendered (45 and 71 shares, respectively) in exchange for exercise of stock options
    		                                                                               
      changes in fair value of contingent consideration liability related to acquisitions
    		                                                                               
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2013 and 2012
    		                                                                               
      supplemental disclosures of cash flow information —
    		                                                                               
      merit common stock surrendered (45 and 103 shares, respectively) in exchange for exercise of stock options
    		                                                                               
      excess tax benefit from stock-based compensation
    		                                                  -53,000                             
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2013 and 2012
    		                                                                               
      write-off of patents and license agreement
    		                                                                               
      goodwill impairment charge
    		                                                                               
      purchase of trading investments
    		                                                                               
      unrealized gains on trading investments
    		                                                                               
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2012, 2011 and 2010
    		                                                                               
      borrowings on line of credit
    		                                                                               
      payments on line of credit
    		                                                                               
      merit common stock surrendered (131, 78 and 0 shares, respectively) in exchange for exercise of stock options
    		                                                                               
      (gain) loss on sales and/or abandonment of property and equipment
    		                                                                               
      tax benefit attributable to appreciation of common stock options exercised
    		                                                    -265,000                       693,000   536,186 
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2012 and 2011
    		                                                                               
      merit common stock surrendered (71 and 103 shares, respectively) in exchange for exercise of stock options
    		                                                                               
      merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2011, 2010 and 2009
    		                                                                               
      common stock repurchased and retired
    		                                                                               
      acquisition purchases in other long term obligations
    		                                                                               
      merit common stock surrendered (78, 0 and 27 shares, respectively) in exchange for exercise of stock options
    		                                                                               
      write-off of certain patents and trademarks
    		                                                     42,000 3,000 14,000  84,000 0 24,000    27,000   40,000 150,000 60,000   0 0 0 40,000 36,000 15,000 14,000 209,507 
      impairment of goodwill
    		                                                                               
      net unrealized losses on trading investments
    		                                                               237,000                
      stock-based compensation
    		                                                     436,000 311,000 335,000  344,000 302,000 304,000  305,000 277,000 298,000 293,000 239,000 98,000 371,000 363,000 249,000 147,000 306,000 432,000 374,000 390,000     
      income tax refunds receivable
    		                                                                      3,000    955,000     
      liabilities related to unrecognized tax positions
    		                                                                     166,000 163,000         
      other long-term assets
    		                                                                               
      proceeds from sale of marketable securities
    		                                                                               
      net unrealized gains on trading investments
    		                                                                               
      write-off of certain patents and license agreement
    		                                                                               
      unrealized (gains) losses on trading investments
    		                                                                               
      current liabilities related to unrecognized tax benefits
    		                                                                               
      non-current liabilities related to unrecognized tax benefits
    		                                                                               
      net unrealized losses (gains) on trading investments
    		                                                                               
      changes in operating assets and liabilities net of effects from acquisitions:
    		                                                                               
      deposits
    		                                                                   6,000 0 0 6,000 7,000        
      net unrealized (gains)/losses on trading investments
    		                                                                               
      tax benefit attritutable to appreciation of common stock options exercised
    		                                                                               
      excess tax benefit attributable to appreciation of common stock options exercised
    		                                                                               
      proceeds from sale of trading investments
    		                                                                               
      current liabilities related to unrecognized tax positions
    		                                                                               
      non-current liabilities related to unrecognized tax positions
    		                                                                               
      write-off of a certain patent and trademarks
    		                                                             86,000                  
      purchase of marketable securities available for sale
    		                                                                               
      additions to long-term debt
    		                                                             0                  
      payment on long-term debt
    		                                                                               
      supplemental disclosures of cash flow information—cash paid during the period for:
    		                                                                               
      accrued purchase price
    		                                                               533,000                
      net (decrease)/increase in cash and cash equivalents
    		                                                                               
      proceeds from the sales of property and equipment
    		                                                               5,000                
      supplemental disclosures of cashflow information—cash paid during the period for:
    		                                                                               
      losses on sales and/or abandonment of equipment
    		                                                                332,000 205,000 4,000  182,000 0 70,000         
      write-off of certain patents and a license agreement
    		                                                                               
      sale (purchase) of trading investment securities
    		                                                                               
      income tax benefit of options exercised
    		                                                                               
      proceeds from the sale of equipment
    		                                                                0    0           
      write-off of a certain patent and license agreement
    		                                                                               
      increase in deferred compensation assets
    		                                                                               
      proceeds from:
    		                                                                               
      issuance of common stock
    		                                                                    134,000 329,000 664,000    407,000 1,749,000 973,000 292,000 462,091 
      increase in deferred compensation payable
    		                                                                    -129,000 72,000 81,000  7,000 -1,000 224,000 147,000 146,000 216,000  
      net cash from (used by) financing activities
    		                                                                               
      net increase/(decrease) in cash and cash equivalents
    		                                                                 2,999,000 6,183,000             
      decrease/(increase) in cash surrender value of life insurance contracts
    		                                                                  52,000             
      proceeds from the sales of equipment
    		                                                                  2,000    5,000    8,000     
      (decrease)/increase in deferred compensation payable
    		                                                                               
      adoption of fin 48
    		                                                                               
      impairment of assets
    		                                                                               
      increase in cash surrender value of life insurance contracts
    		                                                                               
      cash paid in acquisitions—net of cash acquired
    		                                                                               
      other liabilities
    		                                                                           -12,000 -12,000 137,000  
      principal payments on long-term debt
    		                                                                               
      net cash (used by) provided by financing activities
    		                                                                               
      net(decrease)/increase in cash and cash equivalents
    		                                                                               
      note receivable
    		                                                                               
      losses on sales and/or disposals of property and equipment
    		                                                                               
      bad debt expense
    		                                                                        57,000 0 24,000 11,000 -8,000 32,000 16,063 
      excess tax benefits for stock-based compensation
    		                                                                               
      adjustments to reconcile net income to net cash
    		                                                                               
      provided by operating activities:
    		                                                                               
      losses (gains) on sales of property and equipment
    		                                                                              -279 
      changes in operating assets and liabilities
    		                                                                               
      net of effects from acquisitions:
    		                                                                               
      net increase in cash and
    		                                                                               
      cash equivalents
    		                                                                               
      supplemental disclosures of cash
    		                                                                               
      flow information—cash paid during
    		                                                                               
      the period for:
    		                                                                               
      losses on sales and abandonment of equipment
    		                                                                          29,000     
      changes in operating assets and liabilities net of effects from acquisition:
    		                                                                               
      other long-term obligation
    		                                                                               
      cash paid in acquisition
    		                                                                               
      losses on sales of property and equipment
    		                                                                               
      changes in operating assets and liabilities:
    		                                                                               
      net of effects from acquisition:
    		                                                                               
      changes in operating assets and liabilities: net of effects from acquisition:
    		                                                                               
      deferred credits
    		                                                                               
      tax benefit attributable to appreciation of
    		                                                                               
      common stock options exercised
    		                                                                             36,000  
      employee and other receivables
    		                                                                               
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.